Several studies and clinical cases have noted suboptimal blood levels of B12 in those who have taken metformin for extended periods. The National Nutrition and Health Examination reviewed the blood work on 1,621 people with diabetes, more than a third of whom were taking metformin, and demonstrated a reduction in serum B12 levels in people […]
The study, which was published in the journal Nature, focused on the role of insulin-degrading enzyme (IDE). This enzyme helps to break down insulin, so finding a way to block its function could lead to new treatments for diabetics, the researchers speculated. In their work, the team was able to find a molecule called 6bK […]
This week Wil’s sharing his thoughts on some, er… funky side effects of diabetes medications. Are they real, rare or just figments of our D-imagination? Here’s what Wil thinks
“In patients with type 2 diabetes inadequately controlled by diet and exercise, canagliflozin 100 and 300 mg provided significant dose-dependent reductions in HbA1c and body weight compared with placebo,” William Canovatchel, MD, said during his presentation.
Eli Lilly and Co said its type 2 diabetes drug was more effective than Sanofi SA’s approved drug Lantus in reducing patients’ blood sugar levels in three late-stage trials.
After a phase III study that showed no reduction in cardiovascular events for those with diabetes, continued trials for the diabetes drug Aleglitazar have been scrapped. The results were revealed at the 2014 American College of Cardiology Scientific Sessions.
As we know, all medications have side effects and many medications can interact with either other drugs or the foods that we eat. That makes it all the more important that you both understand why you are taking the drugs you are prescribed and how they work.
Cleveland-based Thermalin said today that JDRF will provide it with up to $1 million for specific milestones related to identifying a clinical candidate insulin analog with a shorter tail of action.
A little pee could go a long way in helping type 1s get their blood sugars in line. At least that’s what researchers think about the new class of drugs known as SGLT-2 inhibitors, which are designed for use in people with type 2 but are also becoming a potential treatment for type 1s.
A three-decade study from researchers at the University of Miami found that chromium supplements are not useful in lowering fasting glucose levels in either healthy individuals or those with diabetes.
Researchers at Boston University of School of Medicine (BUSM) found that Pramlintide, a relatively new drug used to treat both type 1 and type 2 diabetes, reduces the presence of amyloid-beta peptides, an amino acid that is present in higher levels in the brains of those with Alzheimer’s, and essentially toxic to nerve cells.
Tanzeum “can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes,” Dr. Curtis Rosebraugh, director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research, said in an agency news release
Lexicon Pharmaceuticals Inc said its experimental drug to treat diabetes reduced the use of insulin at meal times in a mid-stage study of patients with type 1 diabetes, sending the company’s shares up as much as 17 percent.
Glucagon injections are used to treat people with severe hypoglycemia who cannot swallow food or liquid due to sleepiness, unconsciousness, or seizures. However, mixing and administering the injection can be difficult for bystanders who don’t have medical training.
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is currently not FDA approved; it is used in many other countries, such as Japan, India and Europe, as a dual oral agent with metformin or thiazolidinediones.
The FDA is considering a medicine that would be a weekly shot. And it’s not insulin. It’s a hormone called albiglutide — to be marketed by Glaxo Smith Kline as Eperzan.
The FDA will delay allowing the type 2 drug empagliflozin to enter the U.S. market until “previously observed deficiencies” at the plant where it is manufactured are fixed. The delay does not call into question the safety or utility of the drug, which is manufactured by Eli Lilly and Boehringer Ingelheim.
Is the usage of these drugs increasing because of their glorious results or have the pharmaceutical companies trained our nation into simply becoming repeat customers?
Roughly 75% of older Americans have multiple chronic conditions, and more than 20% of them are taking medicines that work at cross-purposes — improving one of their conditions while worsening another — according to new a new study in the journal PLoS One.
It was long believed that by virtue of their glucose-lowering properties diabetes drugs would confer substantial cardiovascular benefits. Now, however, that belief is no longer widely held and the FDA now requires cardiovascular outcome trials for new diabetes drugs.